ArticlePediatric pulmonology2026
Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants.
Article in Pediatric pulmonology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants.Pediatric pulmonology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRespiratory syncytial virus (RSV) is the leading cause of bronchiolitis and hospitalization in infants. Since 2023, France has implemented two preventive strategies aimed at reducing RSV burden: long-acting monoclonal antibody nirsevimab and RSV vaccine for pregnant women, the latter becoming available from September 2024. This study aimed to assess the impact of RSV preventive strategies on the clinical severity and viral epidemiology of bronchiolitis in hospitalized infants. MATERIAL AND
methodsWe conducted a retrospective study at Armand Trousseau University Hospital, including infants under 12 months hospitalized for a first episode of bronchiolitis between October and March during four winter seasons (2021-2025). Clinical and virological data were compared between the pre-intervention (2021-2023) and post-intervention (2023-2025) periods. Subgroup analyses were performed based on RSV infection and prophylaxis status.
resultsA total of 509 infants were included (292 pre-intervention, 217 post-intervention). Post-intervention infants were older (median, 3.2 vs. 1.9 months, p = 0.001), required less oxygen therapy (58.5% vs. 70.9%, p < 0.001), and had shorter hospital stays (median, 3.0 vs. 5.0 days, p < 0.001). Compared with untreated infants (n = 140), those who received nirsevimab (n = 67) had significantly lower rates of RSV infection and viral co-infections (OR: 0.15 (95%CI: 0.08-0.29), p < 0.001; and 40.4% vs. 25.0%, p = 0.035), while human metapneumovirus was detected more frequently (OR: 11.00 (95%CI: 3.50-34.55), p < 0.001). DISCUSSION AND
conclusionDuring the period following the introduction of RSV preventive strategies, a reduced hospital burden, milder clinical courses, and shifts in viral epidemiology were observed. These findings support the continued implementation of RSV immunoprophylaxis and underscore the importance of ongoing surveillance to monitor its long-term impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.